Calicheamicin

By Targets:	ADC Antibody (1) ADC Cytotoxin (2) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (2) Bacterial (2) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1)
By Research Areas:	Cancer (4) Infection (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19609

*Calicheamicin* 5+ Cited Publications Calicheamicin γ1	DNA Alkylator/Crosslinker ADC Cytotoxin Bacterial Apoptosis Antibiotic	Infection Cancer
Calicheamicin, an antitumor antibiotic, is a cytotoxic agent that causes double-strand DNA breaks. Calicheamicin is a DNA synthesis inhibitor . Calicheamicin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19791

N-Acetyl-Calicheamicin N-Acetyl-Calicheamicin γ; N-Acetyl-γ-Calicheamicin	ADC Cytotoxin DNA/RNA Synthesis Antibiotic Bacterial	Infection Cancer
N-Acetyl-Calicheamicin (N-Acetyl-Calicheamicin γ), an enediyne anti-tumor antibiotic, is an ADC cytotoxin. N-Acetyl-Calicheamicin can induce DNA damage, and can be used in the synthesis of ADC .

HY-109539

Gemtuzumab ozogamicin	Antibody-Drug Conjugates (ADCs) Apoptosis	Cancer
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic drug Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML) .

HY-P99971

Gemtuzumab	ADC Antibody	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library	92 compounds
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide. The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 92 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Toxins for Antibody-Drug Conjugate Research Library

92 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 92 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Target	Research Area

HY-P99971

Gemtuzumab	ADC Antibody	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.